October 1, 2024

Supplementary Figure S3 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Supplementary Figure S3. Semi-supervised hierarchical clustering of the DEGs comparing TOXlowvs TOXhighin CD4+cells from COMBO-treated patients (n = 78) identified from PPI analysis.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Monson et al. (Tue,) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efef7c https://doi.org/https://doi.org/10.1158/1078-0432.27142342

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma2024
2Supplementary Figure S5 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma2024
3Supplementary Figure S2 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma2024
4Supplementary Figure S6 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma2024
5Supplementary Figure S1 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma2024

Preguntar a la IA

Me gusta

Guardar